Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | HTR1F | P30939 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972939 | 0.85 | POLB (0.49) | POLBJAK2JAK1JAK3FLT3 | |
| SCHEMBL6154056 | 0.82 | ROCK2 (0.66) | JAK2JAK1ROCK2PTGS1PTGS2 | |
| SCHEMBL6154237 | 0.82 | ROCK2 (0.51) | ROCK2PTGS1PTGS2FLT3 | |
| SCHEMBL6154234 | 0.82 | ROCK2 (0.51) | ROCK2PTGS1PTGS2FLT3 | |
| SCHEMBL6153723 | 0.82 | ROCK2 (0.66) | JAK2JAK1ROCK2PTGS1PTGS2 | |
| SCHEMBL6153721 | 0.82 | ROCK2 (0.66) | JAK2JAK1ROCK2PTGS1PTGS2 | |
| SCHEMBL6154425 | 0.82 | EHMT2 (0.50) | POLBJAK2JAK1JAK3FLT3 | |
| SCHEMBL6154643 | 0.81 | ALDH1A1 (0.60) | JAK2JAK1PARP1MAPT | |
| SCHEMBL6156769 | 0.81 | ROCK2 (0.47) | JAK2JAK1ROCK2PTGS1PTGS2 | |
| SCHEMBL6154351 | 0.81 | PTGS1 (0.52) | POLBJAK2JAK1ROCK2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | ACKR3 884/4885POLB 4155/4885JAK2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.